Target Identification in Anti-Tuberculosis Drug Discovery

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a global epidemic despite being preventable and curable.
• Challenges in TB drug discovery include Mtb's drug resistance, latent forms, cell wall permeability, and efflux pumps.
• Current TB therapies target a small fraction of bacterial proteins, highlighting the need for new therapeutic strategies.

Purpose of the Study:

• To review current challenges in TB drug discovery.
• To highlight emerging druggable proteins in Mtb.
• To explain the role of chemical probes in identifying new targets and biomarkers for TB.

Main Methods:

• Review of existing literature on TB drug discovery challenges and Mtb protein targets.
• Discussion of the application of chemical probes for protein profiling in Mtb.
• Analysis of how identified targets and biomarkers can lead to new therapeutic and diagnostic approaches.

Main Results:

• Limited knowledge of Mtb pathophysiology and inadequate in vitro/in vivo models hinder drug discovery.
• Emerging druggable Mtb proteins offer new avenues for therapeutic intervention.
• Chemical probes facilitate the identification of novel Mtb targets and biomarkers.

Conclusions:

• Overcoming challenges in TB drug discovery requires identifying new targets and developing better models.
• Chemical probes are valuable tools for discovering novel druggable proteins and biomarkers in Mtb.
• Advancements in target identification can lead to disruptive therapeutic regimens and diagnostic tools for TB.